VKTX241004P65000
- 2.48
- -1.83-42.46%
Viking Therapeutics Newsroom
New Small-cap Buy and Sell Ideas for Oppenheimer's 50/50 List
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Is Viking Therapeutics Inc. (VKTX) the Best Performing Small-Cap Stock in 2024?
Oppenheimer points out the next "trend" for weight loss drugs: oral over-the-counter medication.
The competition to develop oral weight-loss drugs is intensifying.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Viking Therapeutics Unusual Options Activity For September 24
Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
10 Health Care Stocks With Whale Alerts In Today's Session
US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?
Skye Stock Rallies 22% Following Weight-loss Drug Update
Amgen Vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
Viking Therapeutics Insider Sold Shares Worth $715,850, According to a Recent SEC Filing
Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers' Target?
Viking Therapeutics(VKTX.US) Officer Sells US$15.31 Million in Common Stock